ALDO MORAN: Open Payments
NPI 1649730946 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$464 in 14 payments from 9 companies in 2025. Trend: 2023 $25 · 2024 $255 · 2025 $464
Food & beverage: $464
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $160 |
| AstraZeneca Pharmaceuticals LP | 3 | $145 |
| Lilly USA, LLC | 2 | $36 |
| SANOFI PASTEUR INC. | 1 | $25 |
| Amgen Inc. | 1 | $24 |
| PFIZER INC. | 1 | $21 |
| Exact Sciences Corporation | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Novo Nordisk Inc | 1 | $15 |
Products named: JARDIANCE, FARXIGA, FLUZONE HIGH-DOSE, REPATHA, PREVNAR 20, The Cologuard Plus Collection Kit, MOUNJARO, NEXLETOL.
Industry payments across TX — which companies pay providers there.
